Bluetongue virus (BTV) is an arbovirus transmitted by blood-feeding midges to a wide 27 range of wild and domestic ruminants. In this report, we showed that BTV, through its virulence 28 non-structural protein NS3 (BTV-NS3), is able to activate the MAPK/ERK pathway. In 29 response to growth factors, the MAPK/ERK pathway activates cell survival, differentiation, 30 proliferation and protein translation but can also lead to the production of several inflammatory 31 cytokines. By combining immunoprecipitation of BTV-NS3 and mass spectrometry analysis 32 from both BTV-infected and NS3-transfected cells, we identified the serine/threonine-protein 33 cascade. Furthermore, the intrinsic ability of BTV-NS3 to bind BRAF and activate the 37 MAPK/ERK pathway is conserved throughout multiple serotypes/strains but appears to be 38 specific to BTV compared to other members of Orbivirus genus. Inhibition of MAPK/ERK 39 pathway with U0126 reduced viral titers, suggesting that BTV manipulates this pathway for its 40 own replication. Therefore, the activation of the MAPK/ERK pathway by BTV-NS3 could 41 benefit to BTV replication by promoting its own viral protein synthesis but could also explain 42 the deleterious inflammation associated with tissue damages as already observed in severe cases 43 of BT disease. Altogether, our data provide molecular mechanisms to explain the role of BTV-44 NS3 as a virulence factor and determinant of pathogenesis. 45 author/funder. All rights reserved. No reuse allowed without permission.
proteins of the outer capsid VP5 and the most variable of BTV protein VP2 representing the 84 main target of neutralizing antibodies and determines the serotype specificity (15, 16). Non-85 structural proteins contribute to the control of BTV replication (17), viral protein synthesis (18), 86 maturation and export from the infected cells (19-23). Initially described for NS4, NS3 has also 87 been shown to counteract the innate immune response, and in particular the type I interferon 88 (IFN-α/β) pathway (13, 24, 25) . 89 NS3 is encoded by the segment 10 and expressed as two isoforms, NS3 and NS3A, the 90 latter being translated from an second in-frame start codon by which the first N-terminal 13 91 amino acids residues are lacking (26). NS3 proteins are glycoproteins that promote viral release 92 either through its viroporin activity (20) or by budding. This latter implies interactions between 93 NS3 and outer capsid VP2/VP5 proteins (27), and cellular proteins involved in the pathway of 94 endosomal sorting complexes required for transport (ESCRT) (TSG101 and NEDD4-like 95 ubiquitin ligase) and the calpactin light chain p11 (23, 28, 29) . Altogether, these reports provide 96 molecular basis of the multifunctional role of BTV-NS3 as a virulence factor and determinant 97 of pathogenesis as also illustrated by other in vivo studies using BTV monoreassortants and 98
NS3/NS3A knockout mutants (30-32). 99
Many viruses can modulate and hijack signaling pathways related to the mitogen-100 activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway for more 101 efficient replication (33). In response to extracellular stimuli such as growth factors, several 102 downstream components of the MAPK/ERK pathway including RAS, RAF, MEK1/2 and 103 ERK1/2 are successively activated. Then, ERK1/2 directly or indirectly regulates transcription 104 factors (e.g. Elk1) involved in cell proliferation, differentiation and survival (34, 35) but also 105 cellular factors that control mRNA translation like eukaryotic initiation factor 4E (eIF4E) (36). 106
Results

116
BTV-NS3 activates the MAPK/ERK signaling pathway 117
To address the question of BTV modulation with the MAPK/ERK pathway, we used a 118 trans-reporter gene assay that measures Elk1 activation by ERK1/2. In this system, Elk1 119 transcription factor is fused to the DNA binding domain of Gal4 (Gal4-DB) and leads to the 120 expression of the firefly luciferase reporter gene downstream of a promoter sequence containing 121 a Gal4 binding site. Upon stimulation with a growth factor like EGF, Elk1 was activated as 122 assessed by a 5-fold increase of luciferase activity compared to unstimulated HEK-293T cells 123 ( Figure 1A ; mock control). Cells infected with BTV at different MOIs showed a very strong 124 enhancement in this cellular pathway, even in absence of EGF stimulation ( Figure 1A) , and in 125 a MOI-dependent manner. Moreover, the inability of a UV-inactivated BTV to activate the 126 luciferase reporter gene indicated that the induction of MAPK/ERK was dependent on viral 127 replication or de novo viral protein expression. To determine whether viral protein(s) could be 128 involved in the MAPK/ERK activation, we tested separately all the BTV proteins in our reporter 129 assay. As shown in Figure 1B , only BTV-NS3 is able to strongly activate the MAPK/ERK 130 pathway both in presence or absence of EGF stimulation. Thus, the activation of the 131 (with Mascot scores of 64 and 104, respectively) whereas BRAF was not detected in the control 140 conditions (mock infected-or empty pCI-neo-3xFLAG transfected-cells). The identified 141 peptides corresponding to BRAF are listed in Table 1 . 142 BRAF, together with ARAF and CRAF, are members of the RAF kinase family that 143 play a central role in regulating the MAPK/ERK signaling pathway. Therefore, binding to 144 BRAF represents a potential molecular mechanism underlying this manipulation that we 145 decided to investigate. To validate this interaction, full-length BTV-NS3 (NS3FL) and different 146 fragments of NS3 ( Figure 2A ) were tested for their ability to interact with endogenous BRAF. 147
To do so, GST-tagged NS3FL or indicated fragments were expressed in HEK-293T cells and 148 purified 48 h later with glutathione-sepharose beads. As shown in Figure 2B , endogenous 149 BRAF copurified only with NS3FL. 150
Using the same luciferase assay, we showed that only full-length BTV-NS3 is able to 151 enhance Elk1 activation ( Figure 2C ). In contrast, the indicated fragments of NS3 were unable 152 to do so, consistently with the previous pull-down assays ( Figure 2B ). Altogether, these results 153 demonstrate that only the full-length BTV-NS3 interacts with BRAF and activates the 154 MAPK/ERK signaling pathway. 155
156
Phosphorylation of ERK1/2 and eIF4E is stimulated by BTV infection and in cells 157
expressing BTV-NS3 158
To further decipher the impact of BTV-NS3 on the MAPK/ERK signaling pathway, we 159 compared the phosphorylation kinetics of ERK1/2 and eIF4E in HEK-293T cells infected by 160 BTV ( Figure 3A ) and in cells expressing BTV-NS3 ( Figure 3B ). HEK-293T cells were infected 161 with BTV (MOI=0.01) and 24 h later, cells were serum-starved for 12 h before being stimulated 162 with EGF. Phosphorylation levels of ERK1/2, determined at 10, 30, 120 min, 6 h and 24 h after 163 stimulation, were markedly and reproducibly higher after BTV infection compared to mock 164 author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/562421 doi: bioRxiv preprint control ( Figure 3A) . Interestingly, we observed that BTV also induced ERK1/2 165 phosphorylation even in absence of EGF stimulation. This is reminiscent to what was observed 166 for Elk1 activation ( Figure 1A) showing a significant activation of the MAPK/ERK pathway 167 by BTV. In parallel, we also determined the phosphorylation level of the translation initiation 168 factor eIF4E, a downstream target of this pathway that is involved in the control of mRNA 169 translation. In contrast to ERK1/2, the phosphorylation level of eIF4E in BTV infected-cells 170 was increased only at later time points after EGF stimulation whereas p-eIF4E decreased in 171 mock condition ( Figure 3A) . 172
In parallel to the BTV infectious context, cells were transfected with 3xFLAG-tagged 173 BTV-NS3 or a control plasmid. After 24 h, cells were serum-starved and the phosphorylation 174 levels of ERK1/2 and eIF4E were measured at the same time points post-EGF stimulation as 175 before. Like BTV infection, similar phosphorylation kinetics of ERK1/2 and eIF4E were 176 observed for BTV-NS3 expression alone ( Figure 3B ). In conclusion, these phosphorylation 177 kinetics confirm that either BTV infection or transient expression of BTV-NS3 can both 178 activate the MAPK/ERK pathway. 179
180
BRAF intracellular localization is modified by BTV 181
Although HEK-293T are highly efficient for transfection and support BTV replication, 182 we aimed to complement our analysis by carrying out similar experiments using a cell line 183 derived from a host naturally infected by BTV. To do so, we measured phosphorylation levels 184 of ERK1/2 in a bovine kidney cell line (MDBK). MDBK cells were serum-starved and infected 185 with BTV at different MOIs for 24 h. As shown in Figure 4A , BTV increased phosphorylation 186 levels of ERK1/2 in a MOI-dependent manner, which is consistent to what was observed for 187
Elk1 activation in HEK-293T cells infected with BTV ( Figure 1A) . 188 author/funder. All rights reserved. No reuse allowed without permission.
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To test if this inhibitor could have an antiviral effect on BTV replication, HEK-293T cells were 211 treated with MEK1/2 inhibitor U0126 and infected with BTV (MOI=0.01). As shown in Figure  212 5C, HEK-293T cells treated with U0126 exhibited significant lower viral titers compared to the 213 author/funder. All rights reserved. No reuse allowed without permission.
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Considering that its aberrant activation represents an important step toward carcinogenesis, the 271 modulation of the MAPK/ERK pathway has been initially described for DNA tumor viruses 272 and oncogenic retroviruses. However, non-oncogenic RNA viruses are also able to activate this 273 signaling cascade even if the molecular mechanisms underlying this manipulation, in particular 274 in term of protein-protein interactions, often remain a pending question. 275
In this report, we show that BTV activates the MAPK/ERK pathway as assessed by 276
Elk1 transactivation and phosphorylation levels of ERK1/2 and eIF4E, which is reminiscent to 277 findings of Mortola and colleagues (37), but we also give the first example of a BTV protein 278 that contributes to this positive regulation. We further demonstrate that both BTV infection and 279 NS3 expression alone also activate the MAPK/ERK pathway in the absence of external stimuli. The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/562421 doi: bioRxiv preprint
In addition, we have confirmed this activation in both human and bovine cells. One possible 288 explanation could be that, in contrast to these previous studies, all of our experiments were 289 performed under starvation conditions, which is likely to be essential since the MAPK/ERK 290 pathway is activated in response to growth factors. 291
In contrast to BTV, NS3 proteins from EHDV, AHSV and EEV are unable to activate 292 the MAPK/ERK pathway suggesting that BTV-NS3 is likely to be functionally distinct from 293
other Orbiviruses NS3 proteins. Although BTV-NS3 shares several domains with EHDV-NS3, 294
AHSV-NS3 and EEV-NS3 (e.g. the amphipathic helix at the N terminus, the late-domain 295 motifs, the extracellular and the two transmembrane domains) (23, 42), these proteins are 296 genetically different. Indeed, the NS3 proteins of AHSV and EEV only share »30% of sequence 297 homology with BTV-NS3 whereas the protein sequence is more conserved between BTV-NS3 298 and EHDV-NS3 (57% of sequence homology), which is consistent with the fact that both BTV 299 and EHDV are transmitted to ruminants. Although we have currently no explanation for this 300 apparent specificity of BTV, these differences in protein sequence could account for their 301 capacity or incapacity to activate the MAPK/ERK pathway. Nevertheless, further investigations 302 will be needed to understand how the MAPK activation could provide an advantage for BTV 303 at molecular/cellular level in comparison to other orbiviruses. 304
Considering that ERK1/2 regulate more than 160 downstream target factors (43) The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/562421 doi: bioRxiv preprint Rhesus and group A rotaviruses also activate MAPK/ERK pathway to facilitate viral replication 338 and viral uncoating, respectively (66, 67) . A possible link between MAPK/ERK pathway and 339 BTV protein expression could be related to the downstream targets of this pathway which are 340 essential factors of the cellular translational machinery, like eIF4E. 341 eIF4E is believed to be the least abundant of all initiation factors. Therefore, it can be 342 considered as an excellent target to regulate protein synthesis. Phosphorylation of eIF4E is 343 mediated by MAPK interacting kinase 1 (MNK1), itself mainly activated by ERK1/2 (36). 344
However, MNK1 has also other downstream targets including eukaryotic initiation factor 4G 345 (eIF4G). Once activated, eIF4E interacts with the cap structure and brings translation initiation 346 factors together with the small ribosomal subunit via the scaffold protein eIF4G to initiate cap-347 dependent mRNA translation (68). Since BTV mRNA are capped like their host counterparts 348 (69, 70), it may be assumed that BTV increases phosphorylation level of eIF4E, thereby 349 stimulating cap-dependent translation, to promote its own viral protein synthesis within infected 350
cells. 351
Our findings support a model where BTV-NS3 interacts with BRAF to activate 352 MAPK/ERK pathway. To the best of our knowledge, this is the first report demonstrating both 353 BRAF as a target of a viral protein and this interaction as an important step toward a viral 354 manipulation of the MAPK/ERK pathway. We also demonstrate that BTV infection leads to a 355 re-localization of BRAF either at the cell membrane or the Golgi apparatus. Initially described 356 to be mainly regulated at the plasma membrane (71, 72), it has now been clearly established 357 that the control of MAPK/ERK pathway can also occur in the Golgi apparatus (73). Thus, these 358 specific localizations could contribute to the aggregation of NS3-BRAF complexes to enhance 359 MAPK/ERK signaling. Further analyses with confocal microscopy will be needed to confirm 360 the colocalization between NS3 and BRAF and additional biochemical investigations are still 361 required to decipher how this viral protein activates BRAF and the downstream events of this 362 author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/562421 doi: bioRxiv preprint pathway. Altogether, NS3 interactions with BRAF represents a potential target for the 363 development of antiviral molecules against BTV. 364 author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/562421 doi: bioRxiv preprint
Materials and Methods 365
Cell lines and viral infections 367
HEK-293T and MDBK cells were maintained in Dulbecco's modified Eagle's medium 368 (DMEM; Gibco-Invitrogen) containing 10% fetal bovine serum, penicillin, and streptomycin 369 at 37°C and 5% CO2. BTV8 WT strain was amplified and titrated on BSR-T7. Inactivated virus 370 was prepared by exposing live virus to 254-nm UV as previously described (74). Serum-free 371 medium was used as an inoculum for BTV-infected cells. BTV infection was analyzed at the 372 indicated time points using a specific NS3 antibody (kindly provided by Dr. tag and 3xFLAG-tag fusions were achieved using pDEST27 (Invitrogen) and pCI-neo-3xFLAG 388 vector, respectively (82). An expression vector pNRIG-I carrying genes for the constitutively 389 
Co-affinity purification experiments 411
To perform co-affinity purification experiments coupled to mass spectrometry analyses, 412
HEK-293T cells were either infected with BTV8 WT strain or transfected with pCI-neo-413 3xFLAG expression vectors encoding for 3xFLAG alone or fused to BTV-NS3FL. Briefly, 414 
LC-MS/MS analyses 434
Co-immunoprecipitation beads from two independent biological replicates were eluted 435 in Laemmli buffer and run on a 4-12 % acrylamide gel (Invitrogen) and proteins were stained 436 with Coomassie blue (Biorad). The experiment was reproduced one time to obtain two 437 independent biological replicates of the total experiment. For both experiments, three gel plugs 438 were cut for each condition. Plugs were reduced with 10 mM DTT, alkylated with 55 mM 439 author/funder. All rights reserved. No reuse allowed without permission.
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Western blot analysis 465
Purified complexes and protein extracts were resolved by SDS-polyacrylamide gel 466 electrophoresis (SDS-PAGE) on 4-12% NuPAGE Bis-Tris gels with MOPS running buffer 467 and transferred to a nitrocellulose membrane (Invitrogen). Proteins were detected using 468 standard immunoblotting techniques. 3×FLAG-and GST-tagged proteins were detected with a 469 mouse monoclonal HRP-conjugated anti-3×FLAG antibody (M2; Sigma-Aldrich) and a rabbit 470 The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/562421 doi: bioRxiv preprint
490
MAPK inhibitors and BRAF silencing 491
When specified, cells were treated with MEK1/2 specific inhibitor U0126 (20 µM final; 492 Promega). Transfections with siRNAs were performed using JetPRIME (Polyplus) according 493 to the manufacturer's instructions. Control non-specific and BRAF specific siRNAs 494 (SMARTpool: ON-TARGETplus Human BRAF SiRNA) were purchased from Dharmacon 495
and were used at a final concentration of 50 nM. 496 author/funder. All rights reserved. No reuse allowed without permission.
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